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Dr Richard Weisel (Toronto, Ontario, Canada). Thank you
very much for an excellent presentation and congratulations to
your group for a very difficult study in these large animal
models. This study represents a real tour de force. The proposal
to enhance mesenchymal stem cell (MSC) engraftment is very
important. Another approach is to use the hydrogels that
were described earlier to improve cell survival. Another
alternative is to reduce the inflammatory phase, as Dr Mayer
discussed earlier, which is a very important concept. Of course
this is what MSCs do normally. The implantation of MSCs into
the heart induces the proliferation of T regulatory cells (Tregs),
1 of the major beneficial effects of MSC treatment. Therefore,
the transplantation of Tregs with MSCs is enhancing the
endogenous repair mechanisms that result from MSC therapy.
This approach is a great idea.
Did you actually improve MSC survival? Was the number of
MSCs in the heart greater with the Tregs?
Dr Zhou. These are good questions. It is difficult to
quantitatively count the total number of these cells at 6 weeks after
injection to see if they increased. However, evidence of an increase
includes the very dense and sphere-shaped clusters surrounded by
thin, layered capsules seen on serial tissue section analysis. These
were never found in the MSC-only injection heart. We believe the
cell number was increased compared with MSC only, but it’s
difficult to give a quantitative answer to this question.
Dr Weisel. Did you improve heart function?
DrZhou.This is preliminary data and this project is still ongoing.
Weare testing the functional improvement by performing stress echo
and magnetic resonance imaging before and after cell transplanta-
tion. The data will be shown in the near future.
Dr Weisel. The cotransplantation of Tregs and MSC was
beneficial for autologous cell therapy but may be very important
for allogeneic cell therapy. As you know, many investigators are
now proposing allogeneic rather than autologous cell therapy
because of the tremendous opportunity to have an off-the-shelf
product for patients who need it, particularly in the operating
room. Have you tried this approach for allogeneic cells?
Cotransplantation of Tregs and MSCs would be much more
relevant for allogeneic cell therapy.
Dr Zhou.We tried allogeneic cell therapy using green fluores-
cent cells and published those results previously. But during that
study we did not involve Tregs. I think it is an excellent idea to
do it in the future.diovascular Surgery c Volume 148, Number 3 1137
